CClinicalTrials.gg
CompletedNCT05348642Updated Mar 2, 2023

Study to Evaluate the Effect of Pasteurized Akkermansia Muciniphila (pAkk) on Complaints Related to IBS

An interventional study of pasteurized A. muciniphila and placebo in Irritable Bowel Syndrome, sponsored by A-Mansia Biotech S.A.. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-02.

Sponsored by A-Mansia Biotech S.A. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Double-blind, randomised, placebo-controlled study to evaluate the benefit of pasteurized Akkermansia muciniphila in reducing complaints related to irritable bowel syndrome.

Further objectives are to evaluate the beneficial potential of pAkk on any anxiety and depression complaints, as well as its safety and tolerability.

Read the detailed description

Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction, globally affecting about 10% of the population. Typical predominant traits are abdominal pain and abnormal bowel habits. The use of probiotics in IBS has been continuously assessed; in recent systematic reviews and meta-analyses, single or combined probiotic strains were indicated to have beneficial effects and good tolerability in the affected population.

pAkk has recently been assessed as a safe novel food ingredient. Beneficial effects and very good tolerability of pAkk have been reported in individuals with metabolic disorders. The objective of the present clinical study - a double-blind, randomised, placebo-controlled, parallel group design, explorative pilot 12-week nutritional study, is to assess the potential of pAkk in IBS management.

The main study objective is then to evaluate the benefit of pAkk in reducing complaints related to irritable bowel syndrome. Further objectives are to evaluate the beneficial potential of pAkk on any anxiety and depression complaints, as well as its safety and tolerability. In total, 90 participants will be enrolled and will attend 4 study visits: one on site and 3 televisits.

02

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • IBS
03

In context

Irritable Bowel Syndrome

1,062 studies on the registry are indexed under Irritable Bowel Syndrome; 190 are open to participants now.

This study's enrollment of 90 is above the median of 71 across 853 interventional studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

A-Mansia Biotech S.A. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Men and women from 18 to 70 years old
  2. Meeting Rome-IV criteria for IBS:

    Recurrent abdominal pain on average ≥1 day/ week in ≥3 months prior to study (with symptom onset ≥6 months prior to study), associated with ≥2 of the following criteria:

    • Related to defecation
    • Associated with a change in frequency of stool
    • Associated with a change in form (appearance) of stool
  3. Consistent and stable body weight in the last 3 months prior to study (less than 5% self-reported change)
  4. Having access to a smartphone or a computer with an internet access, either allowing a video call, and familiar with the use thereof (checked during the visit)
  5. Subject's agreement to comply with study procedures, in particular:

    • to take IP as recommended
    • to avoid the use of other products which may influence the GI complaints during the study
    • to keep the habitual dietary habits, type and level of physical activity (including any specific exercise such as e.g. yoga) as well as the level of caffeine or nicotine (if any)
    • to complete the subject diary and study questionnaires
  6. Women of childbearing potential:

    • commitment to use contraception methods
    • negative pregnancy testing (beta human chorionic gonadotropin test in urine)
  7. Readiness not to participate in another clinical study during this study

Exclusion criteria

Exclusion Criteria:

  1. Self-reported known allergy or hypersensitivity to any of the components of the investigational product
  2. Self-reported nocturnal GI complaints
  3. Women of childbearing potential: self-reported GI complaints mainly related to menstruation
  4. Self-reported lactose or fructose intolerance
  5. Self-reported acute or chronic significant GI disease or digestion/absorption disorders (e.g. inflammatory bowel disease, coeliac disease, pancreatitis, disorders in digestive tract motility etc.)
  6. Self-reported local anorectal problems (e.g. anal fissure, bleeding haemorrhoids)
  7. Self-reported clinically significant findings in colonoscopy within the 2 years prior to study
  8. Family history (immediate family) of colorectal cancer or inflammatory bowel disease; anxiety or depression requiring medication
  9. Acute or chronic psychiatric disease (e.g. depression, anxiety, bipolar disorder) requiring medication
  10. History and/or presence of other clinically significant condition/disorder, which per investigator's judgement could interfere with the results of the study or the safety of the subject, e.g.:

    • unstable thyroid gland disorder
    • unstable hypertension
    • unstable diabetes mellitus
    • eating disorder
    • immunodeficiency
    • relevant gynecological or urological disorder
    • any other relevant serious organ or systemic diseases (e.g. cardiovascular, liver, renal disease etc.)
  11. Significant GI surgery within the last 6 months prior to or planned during the study
  12. Regular medication and/or supplementation within the last month prior to and during the study:

    • antibiotics, probiotics, metformin
    • for management of IBS complaints, such as bile acid binders (e.g. cholestyramine), rifaximin, alosetron, lubiprostone, eluxadoline, linaclotide, peppermint oil
    • that could influence gastrointestinal functions (e.g. laxatives, opioids, systemic corticosteroids, anticho-linergics, anti-diarrheals etc.) as per investigator judgement
  13. Regular use of psychotropic drugs (e.g. hypnotics / sedative drugs, anxiolytics, antidepressants, neuroleptics, anticonvulsants) within 3 months prior to study or adaptogens (e.g. ginseng, St. John's Wort) within 6 weeks prior to and during the study
  14. Introductions of a specific diet (e.g. low carb, vegan, high-fibre, low FODMAP within last 3 months prior to and during the study
  15. Women of child-bearing potential: pregnancy or nursing
  16. History of or current abuse of drugs, alcohol or medication
  17. Participation in another study during the last 30 days prior to and during the study
  18. Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Experimental group receiving pasteurized Akkermansia muciniphila

    pasteurized Akkermansia muciniphila - daily oral dose

    Dietary Supplement: pasteurized A. muciniphila

  • Placebo comparator
    Control group

    Control group receiving placebo, identical to verum regarding the form, size, taste, color and intake.

    Dietary Supplement: placebo

Interventions

  • Dietary supplementpasteurized A. muciniphila

    pasteurized A. muciniphila - oral daily dose

  • Dietary supplementplacebo

    Placebo = identical to verum regarding the form, size, taste, color and intake

06

What researchers measure

Primary outcomes

  1. Irritable Bowel Severity Scoring System / IBS-SSS

    Changes at each timepoint of assessment in comparison to baseline. IBS-SSS is between 0 and 500, with a higher score meaning more severe symptoms.

    Time frame: From baseline to day 14, day 42 and day 84

Secondary outcomes

  1. Irritable Bowel Syndrome-Global Improvement Scale / IBS-GIS

    Changes at each timepoint of assessment in comparison to baseline. The IBS-GIS is a single item assessment of overall IBS symptoms. It poses the question to study participants "How would you rate your IBS signs or symptoms over the past 7 days": Subjects respond on a scale of 1-7 where: 1 = Significantly relieved, 2 = Moderately relieved, 3 = Slightly relieved, 4 = Unchanged, 5 = Slightly worse, 6 = Moderately worse, 7 = Significantly worse.

    Time frame: From baseline to day 14, day 42 and day 84

  2. 3-day diary data on stool frequency

    Changes at each timepoint of assessment in comparison to baseline

    Time frame: From baseline to day 84

  3. 3-day diary data on stool consistency (Bristol Stool Form Scale / BSFS)

    Changes at each timepoint of assessment in comparison to baseline. The Bristol Stool Form Scale is a 7 score visual scale to measure stool consistency. (1) Separate hard lumps like nuts (difficult to pass); (2) Sausage-shaped but lumpy; (3) Like a sausage but with cracks on its surface; (4) Like a sausage or snake, smooth and soft; (5) Soft blobs with clear-cut edges (passed easily); (6) Fluffy pieces with ragged edges, a mushy stool; (7) Watery, no solid pieces, entirely liquid.

    Time frame: From baseline to day 14, day 42 and day 84

  4. Hospital Anxiety and Depression Scale / HADS

    Changes at each timepoint of assessment in comparison to baseline. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.

    Time frame: From baseline to day 14, day 42 and day 84

  5. SF-12: 12-item Short Form survey

    Changes at each timepoint of assessment in comparison to baseline. The SF-12 consists of 12 items questioned weighted and summed to provide physical and mental health scores (PCS and MCS). The two composite scores are computed using the scores on twelve questions that range from 0 to 100, with higher score indicating better health.

    Time frame: From baseline to day 42 and day 84

  6. Global evaluation of tolerability by subject and investigator

    Changes in comparison to baseline. 8 weeks after the baseline, the subjects and the investigator will rate the tolerability of the IP by means of a global scaled evaluation with "very good", "good", "moderate" and "poor"

    Time frame: From baseline to day 84

07

Study locations

1 site
  • analyze & realize GmbH
    Berlin, 13467, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05348642
Lead sponsor
A-Mansia Biotech S.A.
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
Jul 21, 2022
Primary completion
Jan 6, 2023
Completion
Jan 6, 2023
Last update
Mar 2, 2023

Study contacts

Study Director
study director · A-Mansia Biotech

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion